Trials / Terminated
TerminatedNCT03834220
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Debiopharm International SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Debio 1347 | Debio 1347 oral tablets. |
Timeline
- Start date
- 2019-03-22
- Primary completion
- 2020-12-31
- Completion
- 2022-01-04
- First posted
- 2019-02-07
- Last updated
- 2024-02-07
- Results posted
- 2024-02-07
Locations
105 sites across 23 countries: United States, Australia, Austria, Brazil, Bulgaria, Croatia, Czechia, Denmark, Finland, France, Greece, Netherlands, Norway, Philippines, Poland, Romania, Russia, Singapore, South Korea, Spain, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03834220. Inclusion in this directory is not an endorsement.